Terns Pharmaceuticals, Inc. (TERN)
Terns Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Foster City, CA, US. The stock last traded at $52.95, down 0.03% on the session, giving a market capitalisation of $4.77B. On trailing twelve-month figures it carries a trailing P/E of -51.41, a net margin of 0.0%. Its beta of -0.38 implies it has historically moved less than the broad market.
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Terns Pharmaceuticals, Inc. is most often compared with the following Healthcare names: